Research Foundation, Royal Victoria Eye and Ear Hospital, Dublin, Ireland; National Ophthalmic Pathology, Laboratory, Royal Victoria Eye and Ear Hospital, Dublin, Ireland.
Research Foundation, Royal Victoria Eye and Ear Hospital, Dublin, Ireland; Department of Ophthalmology, Royal Victoria Eye and Ear Hospital, Dublin, Ireland.
Pathol Res Pract. 2024 Sep;261:155500. doi: 10.1016/j.prp.2024.155500. Epub 2024 Jul 27.
Vitreoretinal large B- cell lymphoma (VR- LBCL) is a type of non- Hodgkin lymphoma confined to the eye and central nervous system (CNS). The clinical manifestations of intraocular lymphoma can precede, occur simultaneously with, or follow disease at CNS sites. It differs from other forms of extra-nodal lymphoma; in that it does not involve systemic sites other than CNS.
To analyse the clinical and pathological features, and treatment outcomes of a cohort of patients diagnosed with vitreoretinal lymphoma (VRL) in Royal Victoria Eye and Ear Hospital, Ireland between 2010 and 2024.
Retrospective review of medical records and pathology specimens of patients with ocular involvement in VR- LBCL over 14-year period and a review of the literature.
Eight patients were included. All of them underwent pars plana vitrectomy and were confirmed to have VR- LBCL. The median age at diagnosis was 71 years. Three were men and five were women. Six had bilateral disease and two unilateral. Four of four patients had MYD88 L265P mutation present. Four patients showed a high interleukin-10 (IL-10) to interleukins-6 (IL-6) ratio in keeping with the diagnosis of VRL. Three patients had primary CNS lymphoma with subsequent eye involvement, despite systemic chemotherapy treatment. Of the five patients who presented with ocular lymphoma, two patients had CNS involvement after primary vitreoretinal lymphoma was diagnosed. Of those, one was initially treated with local intravitreal chemotherapy. Three patients had no CNS recurrence. At the time of this study, seven patients of eight are alive, four are disease free and two are on a first- line local chemotherapy treatment. One underwent treatment for CNS relapse. One patient died of the disease before commencing targeted therapy.
This case series demonstrated excellent treatment outcomes for seven patients, alive at the time of the study. Both local radiotherapy and intravitreal chemotherapy achieved good ocular control with acceptable side effects and no significant difference in visual outcome. VRL is a difficult diagnosis and vitreous cytology should be prioritised in cases of vitritis unresponsive to treatment. Analysis of MYD88 L265P mutation and IL- 10: IL- 6 ratio >1 are useful adjuncts in the diagnosis of VR- LBCL, particularly in cases where limited vitreous material makes cytological evaluation challenging.
眼内大 B 细胞淋巴瘤(VR-LBCL)是一种局限于眼和中枢神经系统(CNS)的非霍奇金淋巴瘤。眼内淋巴瘤的临床表现可先于 CNS 部位病变,与 CNS 部位病变同时发生,或后于 CNS 部位病变。它与其他结外淋巴瘤形式不同;因为它不涉及 CNS 以外的全身部位。
分析 2010 年至 2024 年期间在爱尔兰皇家维多利亚眼耳医院诊断为眼内淋巴瘤(VRL)的患者的临床和病理特征及治疗结果。
回顾性分析 14 年间眼内 VR-LBCL 受累患者的病历和病理标本,并对文献进行复习。
共纳入 8 例患者。所有患者均行玻璃体切除术,均确诊为 VR-LBCL。诊断时的中位年龄为 71 岁。男性 3 例,女性 5 例。6 例为双眼受累,2 例为单眼受累。4 例患者存在 MYD88 L265P 突变。4 例患者白细胞介素-10(IL-10)与白细胞介素-6(IL-6)比值高,符合 VRL 的诊断。3 例患者有原发性中枢神经系统淋巴瘤,随后出现眼部受累,尽管进行了全身化疗。5 例以眼部淋巴瘤首发的患者中,2 例在诊断为原发性眼内视网膜淋巴瘤后出现中枢神经系统受累。其中 1 例最初接受局部眼内化疗治疗。3 例患者无中枢神经系统复发。在本研究时,8 例患者中的 7 例存活,4 例无疾病,2 例正在接受一线局部化疗。1 例因中枢神经系统复发接受治疗。1 例患者在开始靶向治疗前死于该疾病。
本病例系列研究显示,7 例患者的治疗结果良好,在研究时均存活。局部放疗和眼内化疗均能获得良好的眼部控制,且副作用可接受,对视力结果无显著影响。VRL 诊断困难,对于治疗反应不佳的眼内炎,应优先进行玻璃体细胞学检查。MYD88 L265P 突变和 IL-10:IL-6 比值>1 分析有助于 VR-LBCL 的诊断,尤其是在玻璃体标本有限,细胞学评估具有挑战性的情况下。